Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:18:05 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:VNDA - VANDA PHARMACE INC - https://www.vandapharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VNDA - Q0.15.91·6.240.85.94-0.09-1.5786.64,3925,7136.11  6.146  5.9259.94  4.14Jun 08May 2715 min RT 2¢

Recent Trades - Last 10 of 5713
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-27 07:00U:VNDANews ReleaseVanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
2026-05-07 18:44U:VNDANews ReleaseVanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
2026-05-06 16:01U:VNDANews ReleaseVanda Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-04 08:00U:VNDANews ReleaseVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS(TM) (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
2026-05-01 16:30U:VNDANews ReleaseVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS(TM) (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
2026-04-29 16:30U:VNDANews ReleaseVanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
2026-04-28 19:12U:VNDANews ReleaseVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
2026-04-22 17:13U:VNDANews ReleaseVanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
2026-04-09 11:02U:VNDANews ReleaseVanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
2026-04-08 16:30U:VNDANews ReleaseVanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS(TM) for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
2026-03-19 16:34U:VNDANews ReleaseVanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
2026-03-03 08:00U:VNDANews ReleaseVanda Announces FDA Grants Landmark Hearing for HETLIOZ(TM) in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
2026-02-26 16:35U:VNDANews ReleaseVanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
2026-02-25 07:18U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
2026-02-20 17:59U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Approval of BYSANTI(TM) (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
2026-02-11 16:01U:VNDANews ReleaseVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-04 18:01U:VNDANews ReleaseVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
2026-01-08 07:00U:VNDANews ReleaseVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ(TM) Supplemental New Drug Application for Jet Lag Disorder
2025-12-30 18:13U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Approval of NEREUS(TM) (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
2025-12-15 07:00U:VNDANews ReleaseVanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis